A Safety Study of SGN-CD19A for B-Cell Lymphoma

Status:	Completed
Conditions:	Blood Cancer, Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	12 - Any
Updated:	10/21/2017
Start Date:	February 2013
End Date:	February 16, 2017

A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin
lymphoma (B-NHL)

Inclusion Criteria:

- Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade
3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology,
Burkitt lymphoma, or B-lineage lymphoblastic lymphoma

- Relapsed, refractory, or progressive disease following at least 1 prior systemic
therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received
intensive salvage therapy.

- Eastern Cooperative Oncology Group status of 0 or 1

- Measurable disease

Exclusion Criteria:

- Allogeneic stem cell transplant (SCT)

We found this trial at

sites

Stanford Cancer Center

Stanford, California 94305

from

Stanford, CA